期刊文献+

天麻钩藤饮对高血压心肌纤维化患者血清炎症指标的影响 被引量:2

The effect of Tianma Gouteng decoction on the expression of serum cytokines in patients with hypertension myocardial fibrosis
下载PDF
导出
摘要 目的探讨天麻钩藤饮对高血压心肌纤维化患者血清中炎症指标IL-6、IL-1β、TNF—α、hs—CRP表达的影响。方法纳入2013年8月至2015年2月我中心确诊为原发性高血压患者112例,按照左室质量指数(left ventricular mass index,LVMI)值将上述患者分为非左室肥厚(non left ventrieular hypertrophy,NLVH)组40例和左室肥厚(left ventricular hypertophy,LVH)组72例,将LVH组患者72例随机分为开博通组35例和天麻钩藤饮37例,均给药4周。观察治疗前后各组患者血压和LVMI变化,及各组患者外周血清中炎症指标IL-6、IL-1α、TNF-α、hs—CRP的表达。结果治疗后三组患者收缩压、舒张压和LVMI较治疗前明显下降(P〈0.01)。治疗前LVH组患者血清IL-6、IL-1B、TNF—α、hs—CRP表达水平较NLVH组显著升高(P〈0.05);治疗4周后,LVH组中两组患者血清IL-6、IL-1B、TNF—α、hs—CRP表达水平均较治疗前显著降低(P〈0.05),治疗后两组血清TNF—α、IL-6、IL—1B、hs—CRP表达水平比较无统计学差异(P〉0.05)。结论天麻钩藤饮可通过抑制TNF—α、IL-6、IL-1B、hs—CRP水平进而阻止高血压心肌纤维化的发生发展。 Objective To study the effect of Tianma Gouteng decoction on the expression of serum cytokines of patients with hypertension myocardial fibrosis. Methods 112 patients with essential hypertension admitted in our center between Aug. 2013 and Feb. 2015 were divided into non left ventricular hypertrophy (NLVH) group (n=40) and left ventricular hypertrophy (LVH) group (n=72) according left ventricular mass index (LVMI). 72 patients in LVH group were randomly divided into captopril group (n=35) and Tianma Gouteng decoction group (n=37). The expression of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β and hs-CRP in serum were measured before and after treatment, the change of blood pressure and LVMI were observed before and after treatment. Results SBE DBP, and LVMI significantly decreased after treatment in all three groups (P〈0.01). Before treatment, the expression of TNF-α, IL-6, IL-1β, and hs-CRP in LVH group were higher than those in NLVH group (P〈0.05); after 4 weeks' treatment, serum TNF-ct, IL-6, IL-1 [3, and hs-CRP significantly decreased in both captopril group and Tianma Gouteng decoction group, while there were no statistically significant differences between two groups (P〉0.05). Conclusion Tianma Gouteng decoction can suppresses the development of hypertension myocardial fibrosis by down-regulating the levels of serum TNF-α, IL-6, IL-1β and hs-CRP.
出处 《国际医药卫生导报》 2016年第9期1216-1219,共4页 International Medicine and Health Guidance News
基金 广州市天河区科技计划项目(201404KW038)
关键词 高血压心肌纤维化 天麻钩藤饮 炎症因子 Hypertension myocardial fibrosis Tianma Gouteng decoction Cytokines
  • 相关文献

参考文献8

  • 1He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J].N Engl J Med, 2005, 353(11):1124-1134.
  • 2张运,徐瑞.心肌纤维化——心力衰竭治疗的新靶标[J].中华医学杂志,2006,86(17):1155-1157. 被引量:28
  • 3Gage JR, Fonarow G, Hamilton M, et al. Beta blocker and angiotensin- converting enzyme inhibitor therapy is associated with decreased Thl/ Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure[J].Neuroimmunomodulation, 2004, 11(3):173-180.
  • 4Yu Q, Watson RR, Marchalonis JJ, et al. A role for T lymphocytes in mediating cardiac diastolic function[J].Am J Physiol Heart Circ Physiol, 2005, 289(2):H643-651.
  • 5胡世云,冼绍祥,赵立诚,等.天麻钩藤饮干预高血压病患者心肌纤维化的临床研究[J].中华实用中西医杂志,2004,4(17):1958—1960.
  • 6Marvar PJ, Thabet SR, Guzik TJ, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension[J].Circ Res, 2010, 107(2):263-270. DOI: 10.1161/CIRCRESAHA.110.217299.
  • 7葛良清,李向平,赵水平,陈友德,邹兰兰.原发性高血压左室肥厚与B型利钠肽及高敏C反应蛋白[J].高血压杂志,2006,14(7):539-542. 被引量:16
  • 8吴明竹.对老年高血压左心室肥厚患者进行血清TNF-α、IL-1β和sVCAM-1水平检测的临床价值[J].当代医药论丛,2014,12(10):227-227. 被引量:1

二级参考文献26

  • 1The international society of hypertension and the European society of hypertension.2003 guidelines for management of hypertension[J].J Hypetens,2003,21:1011-1053.
  • 2Devereux RM,Alonso DR,Lutos EM,et al.Echocardiographyic assessment of left ventricular hypertrophy; comparision to necropsy findings[J].Am J Cardiol,1986,57:450-458.
  • 3Waku S,Iida N,Ishihara T.Significance of brain natriuretic peptide measurement as a diagnostic indicator function[J].Methods Inf Med,2000,39:249-253.
  • 4Buckley MG,Markandu ND,Miller MA,et al.plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension[J].J Hum Hypertens,1993,7:245-250.
  • 5Cataliotti A,Malation LS,Jougasaki M,et al.Circulating natriuretic peptide concentrations in patients with end-stage renal disease:role of brain natriuretic peptide as a biomarker for ventricular remodeling[J].Mayo Clin Proc,2001,76:1111-1119.
  • 6Suzuki M,Yamamoto K,Watanabe S,et al.Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension[J].Am J Med,2000,108:627-633.
  • 7Nishigaki K,Tomita M,Kagawa K,et al.Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy[J].J Am coll cardiol,1996,28:123-142.
  • 8Suzuki M,Hamada M,Yamamoto K,et al.Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events[J].Hypertension Res,2002,25:669-676.
  • 9Berger R,Huelsman M,Stecker K,et al.B-type natriuretic peptide predicts sudden death in patients with chronic heart failure[J].Circulation,2002,105:2391-2396.
  • 10Bautista L E,Lopez-Jaramillo P,Vera L M,et al.Is C-reactive protein an independent risk factor for essential hypertension[J].J Hypertens,2001,19:857-863.

共引文献42

同被引文献15

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部